ENTA
insider transactionsENANTA PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Other·F
Chief Legal Officer
$27.1K
1.9K sh · $14.25
Own -35%
-
Grant·A
Chief Legal Officer
$0
4.2K sh
Own +317%
-
Grant·A
Chief Legal Officer
$0
1.3K sh
Own New
-
Other·F
Chief Business Officer
$46.4K
3.3K sh · $14.25
Own -7%
-
Grant·A
Chief Business Officer
$0
5.0K sh
Own +12%
-
Grant·A
Chief Business Officer
$0
1.6K sh
Own +4%
-
Other·F
Chief Product Strategy Officer
$46.4K
3.3K sh · $14.25
Own -9%
-
Grant·A
Chief Product Strategy Officer
$0
5.0K sh
Own +15%
-
Grant·A
Chief Product Strategy Officer
$0
1.6K sh
Own +5%
-
Other·F
Chief Medical Officer
$48.6K
3.4K sh · $14.25
Own -12%
-
Grant·A
Chief Medical Officer
$0
5.2K sh
Own +22%
-
Grant·A
Chief Medical Officer
$0
1.6K sh
Own +8%
-
Other·F
Chief Scientific Officer
$48.6K
3.4K sh · $14.25
Own -1%
-
Grant·A
Chief Scientific Officer
$0
5.2K sh
Own +1%
-
Grant·A
Chief Scientific Officer
$0
1.6K sh
Own +0%
-
Other·F
Jay R. Luly KEY
President and CEO
$87.7K
6.2K sh · $14.25
Own -1%
-
Grant·A
Jay R. Luly KEY
President and CEO
$0
15.2K sh
Own +2%
-
Grant·A
Jay R. Luly KEY
President and CEO
$0
4.8K sh
Own +1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 11, 2026 | Terry Vance | Grant A | 20.0K | $0 |
| Mar 11, 2026 | Lesley Russell | Grant A | 20.0K | $0 |
| Mar 11, 2026 | Kristine Peterson | Grant A | 20.0K | $0 |
| Mar 11, 2026 | Yujiro S Hata | Grant A | 20.0K | $0 |
| Mar 11, 2026 | Mark G Foletta | Grant A | 20.0K | $0 |
| Mar 11, 2026 | Bruce L A Carter | Grant A | 20.0K | $0 |
| Feb 12, 2026 | Matthew Paul Kowalsky | Other F | 1.9K | $27.1K |
| Feb 12, 2026 | Matthew Paul Kowalsky | Grant A | 4.2K | $0 |
| Feb 12, 2026 | Matthew Paul Kowalsky | Grant A | 1.3K | $0 |
| Feb 12, 2026 | Brendan Luu | Other F | 3.3K | $46.4K |
| Feb 12, 2026 | Brendan Luu | Grant A | 5.0K | $0 |
| Feb 12, 2026 | Brendan Luu | Grant A | 1.6K | $0 |
| Feb 12, 2026 | Tara Lynn Kieffer | Other F | 3.3K | $46.4K |
| Feb 12, 2026 | Tara Lynn Kieffer | Grant A | 5.0K | $0 |
| Feb 12, 2026 | Tara Lynn Kieffer | Grant A | 1.6K | $0 |
| Feb 12, 2026 | Scott T. Rottinghaus | Other F | 3.4K | $48.6K |
| Feb 12, 2026 | Scott T. Rottinghaus | Grant A | 5.2K | $0 |
| Feb 12, 2026 | Scott T. Rottinghaus | Grant A | 1.6K | $0 |
| Feb 12, 2026 | Yat Sun Or | Other F | 3.4K | $48.6K |
| Feb 12, 2026 | Yat Sun Or | Grant A | 5.2K | $0 |
| Feb 12, 2026 | Yat Sun Or | Grant A | 1.6K | $0 |
| Feb 12, 2026 | Jay R. Luly KEY | Other F | 6.2K | $87.7K |
| Feb 12, 2026 | Jay R. Luly KEY | Grant A | 15.2K | $0 |
| Feb 12, 2026 | Jay R. Luly KEY | Grant A | 4.8K | $0 |
About ENTA insider trading
This page tracks insider transactions for ENANTA PHARMACEUTICALS INC (ENTA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.